Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

Posted by Matt Breese on Dec 18, 2020

Find me on:

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for breast cancer (HR+/HER2+) treatments shows that under the pharmacy benefit, about 41% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Breast Cancer HR+HER2+-4Q2020Data snapshot as of Q4 2020

Trends: In March 2020, the FDA expanded the label of Ontruzant (trastuzumab-dttb) to include the availability of a 420 mg multidose vial. The agency initially approved the Herceptin (trastuzumab) biosimilar from Samsung Bioepis Co. Ltd. in January 2019 as a 150 mg single-dose vial for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer and for metastatic breast cancer, gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment.  

To read the full Reality Check on Breast Cancer HR+/HER2+ treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing